# Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)

> **NCT00687544** · PHASE4 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 11 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Hepacivirus
- HIV Infections

## Interventions

- **BIOLOGICAL:** Peginterferon alfa-2b (SCH 054031)
- **DRUG:** Ribavirin (SCH 018908)

## Key facts

- **NCT ID:** NCT00687544
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-12
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687544, "Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00687544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*